Evidence map›Paper›PMID 41607793›Full record

ArticleFrontiers in immunology2025

Antibody levels to variant and conserved

Delesa Damena, Lauren Dang, Amadou Barry, Jonathan P Renn, Santara Gaoussou, Almahamoudou Mahamar, Oumar Attaher, Djibrilla Issiaka, Robert D Morrison, Santosh A Misal and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Delesa DamenaMolecular and Pathogenesis Biomarkers Section, Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States.
Lauren DangBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Amadou BarryMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Jonathan P RennPathogenesis and Immunity Section, Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States.
Santara GaoussouMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Almahamoudou MahamarMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Oumar AttaherMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Djibrilla IssiakaMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Robert D MorrisonPathogenesis and Immunity Section, Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States.
Santosh A MisalMolecular and Pathogenesis Biomarkers Section, Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States.
Alassane DickoMalaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako, Bamako, Mali.
Patrick E DuffyPathogenesis and Immunity Section, Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States.
Michal FriedMolecular and Pathogenesis Biomarkers Section, Laboratory of Malaria Immunology and Vaccinology (LMIV), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Proteins expressed on the surface of Methods: We applied immunoprecipitation followed by mass spectrometry (IP-MS) using plasma samples from susceptible and semi-immune children. We then investigated whether 1) antibody levels to membrane-associated proteins identified by IP-MS, or 2) PfEMP1s expressed in IEs of young children predict reduction in malaria disease. Results: Significant reduction in risk of high parasite density infection was predicted by high antibody levels to DBLγ11 [OR (95%CI): 0.74 (0.63-0.86)] and DBLζ5 [0.80 (0.69-0.93)], as well as two Conclusions: The study showed that high antibody levels against four proteins significantly reduced the odds of high parasite burden in future infections. Our functional study suggests that opsonic phagocytosis may mediate reduction in parasite density by antibodies to DBLγ11 and DBLζ5.

Indexed as

Antibodies, ProtozoanAntigens, ProtozoanMalaria, FalciparumPlasmodium falciparumChildChild, PreschoolErythrocytesFemaleHumansInfantMaleMaliParasite LoadPhagocytosisProtozoan ProteinsAntibodies, ProtozoanAntigens, ProtozoanProtozoan Proteinsparasite densityphagocytosisPlasmodium falciparumPlasmodium falciparum erythrocyte membrane protein 1 (PfEMP1)Plasmodium helical interspersed subtelomeric proteins (PHIST)

Identifiers

PMID41607793
PMCPMC12835252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.